Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agrippal versus Fluvirin influenza vaccine study in healthy participants aged 3 to 64 years
2014-004757-14Phase 3
- Sponsor
- Novartis
- Start
- Nov 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in influenza comparing Agrippal with Fluvirin (2 arms). Primary endpoint: Seroconversion or significant increase in antibody titer at Day 22 for age group 3.
02
Drugs
influenza vaccineinfluenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (uv, formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on 2014-004757-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004757-14.